SNY

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Days

Hours

Mins

Sec

Claim Now

Peers: AZN NVS GSK JNJ LLY MRK PFE ABBV BMY NVO

| Held by: PVAL PPH FVD PID FENI AVDE GMOI BASV BUSA QQQJ

Scroll to Statements

Index	-
Market Cap	103.77B
Enterprise Value	119.02B
Income	5.84B
Sales	49.41B
Book/sh	34.71
Cash/sh	3.75
Dividend Est.	2.47 (5.72%)
Dividend TTM	2.42 (5.60%)
Dividend Ex-Date	May 04, 2026
Dividend Gr. 3/5Y	8.45% 5.14%
Payout	73.36%
Employees	76493
IPO	Jul 01, 2002

P/E	18.08
Forward P/E	8.17
PEG	1.16
P/S	2.10
P/B	1.24
P/C	11.51
P/FCF	9.90
EV/EBITDA	6.12
EV/Sales	2.41
Quick Ratio	0.73
Current Ratio	1.09
Debt/Eq	0.28
LT Debt/Eq	0.22
Option/Short	Yes / Yes

EPS (ttm)	2.39
EPS next Y	5.29
EPS next Q	1.11
EPS this Y	6.04%
EPS next Y	6.73%
EPS next 5Y	7.01%
EPS past 3/5Y	-11.86% -15.52%
Sales past 3/5Y	2.90% 3.69%
EPS Y/Y TTM	-0.23%
Sales Y/Y TTM	11.19%
EPS Q/Q	-29.64%
Sales Q/Q	28.69%
Earnings	Jul 30 BMO
EPS/Sales Surpr.	3.11% 3.35%

Insider Own	0.00%
Insider Trans	-
Inst Own	8.78%
Inst Trans	-2.28%
ROA	3.87%
ROE	6.76%
ROIC	5.71%
Gross Margin	65.90%
Oper. Margin	26.10%
Profit Margin	11.81%
SMA20	0.02%
SMA50	-1.49%
SMA200	-8.02%
Trades

Shs Outstand	2.42B
Shs Float	2.40B
Short Float	0.27%
Short Ratio	2.05
Short Interest	6.43M
52W High	52.68 -18.07%
52W Low	40.89 5.55%
Volatility	2.08% 1.70%
ATR (14)	1.01
RSI (14)	50.10
Beta	0.32
Rel Volume	1.10
Avg Volume	3.13M
Volume	3,459,047

Perf Week	3.25%
Perf Month	0.84%
Perf Quarter	-9.57%
Perf Half Y	-11.45%
Perf YTD	-10.94%
Perf Year	-12.47%
Perf 3Y	-19.93%
Perf 5Y	-17.15%
Perf 10Y	3.83%
Recom	2.29
Target Price	53.60
Prev Close	41.63
Price	43.16
Change	3.68%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-26	Downgrade	BNP Paribas Exane	Outperform → Neutral	$50
Feb-12-26	Downgrade	BofA Securities	Buy → Neutral
Jan-27-26	Initiated	Citigroup	Neutral
Jan-16-26	Downgrade	UBS	Buy → Neutral
Jan-06-26	Downgrade	Barclays	Overweight → Equal Weight
Dec-09-25	Downgrade	Guggenheim	Buy → Neutral
Dec-08-25	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$58
Sep-02-25	Upgrade	Deutsche Bank	Hold → Buy
Aug-08-25	Upgrade	JP Morgan	Neutral → Overweight
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy

Show Previous Ratings

Jun-30-26 06:53AM	Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger (Pharmaceutical Technology)
Jun-26-26 01:38PM	Sanofi Faces EU Probe With Fines Possibly Reaching 10% (GuruFocus.com)
06:46AM	EU hits France's Sanofi with flu vaccine antitrust probe (AFP)
Jun-25-26 09:00AM	REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan (IPO-Edge.com)
Jun-24-26 04:12AM	Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor (BioPharma Dive)
06:21AM	Loading…
Jun-23-26 06:21AM	How Kardigan spun deal leftovers into a $400M IPO (BioPharma Dive)
Jun-22-26 02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
07:12AM	Sanofi swaps R&D leaders; Mercks Prometheus deal pays dividends (BioPharma Dive)
05:21AM	Backed by Sanofi and Roche, Orano Med chases radiopharma leadership (Pharma Voice)
05:05AM	Japan approves Sanofi's Sarclisa combo for MM treatment (Pharmaceutical Business Review)
03:00AM	Bionyra brings in $165M for next-generation immune drugs (BioPharma Dive)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis)
Jun-12-26 05:13PM	DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results (Stocktwits)
Jun-11-26 12:21PM	Drug developers eye sports biggest stage as World Cup fever builds (Pharmaceutical Technology)
Jun-10-26 07:28AM	Sanofi stops immune drug trial in latest research setback (BioPharma Dive)
05:48AM	Loading…
05:48AM	Sanofi Halts Phase 3 CIDP Trial for Riliprubart Following Interim Review (SAN) (InvestorsHub)
Jun-08-26 06:05AM	Sanofi and Owkin partner to develop next-generation biopharma AI agents (Pharmaceutical Business Review)
Jun-01-26 07:17AM	MIT bullish on its Initiative for New Manufacturing at the one-year mark (Manufacturing Dive)
May-29-26 06:06AM	FDA grants priority review for Sanofi's venglustat NDA (Pharmaceutical Business Review)
May-20-26 01:54PM	ATS 2026: Mixed results for Sanofi/Regenerons itepekimab cloud COPD prospects (Clinical Trials Arena)
May-18-26 07:28AM	Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda (Barrons.com)
May-15-26 06:29AM	Sanofis vaccine bump; the new FDA commish (Pharma Voice)
May-06-26 04:50PM	Novavax, Inc. Q1 2026 Earnings Call Summary (Moby)
12:42PM	Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 (PR Newswire)
May-05-26 10:14AM	Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE (InvestorsHub)
Apr-30-26 05:24AM	Regeneron Q1 2026 net income falls 10% to $727m (Pharmaceutical Technology)
Apr-29-26 10:12AM	Regeneron shares slide despite Q1 beat (Proactive)
08:53AM	Regeneron Tops Q1 Estimates on Dupixent Momentum (InvestorsHub)
07:15AM	Regeneron beats first quarter estimates on Dupixent strength (Investing.com)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
03:04AM	Loading…
03:04AM	Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments (GuruFocus.com)
Apr-23-26 07:02AM	Sanofi posts upbeat sales as R&D pressure builds (BioPharma Dive)
06:34AM	Sanofi receives FDA approval for Tzield in paediatric diabetes (Pharmaceutical Business Review)
03:48AM	Sanofi climbs as strong Dupixent sales drive Q1 revenue and profit beat (Investing.com)
Apr-07-26 01:36PM	Sanofis bispecific scores in respiratory diseases but fails in eczema (Clinical Trials Arena)
04:34AM	Sanofi immune drug hopeful posts mixed results in mid-stage tests (BioPharma Dive)
Mar-30-26 05:31AM	Sanofi eczema drug weighed down by mixed results, safety concerns (BioPharma Dive)
Mar-27-26 07:56AM	AstraZeneca lung drug gets surprise win in COPD trials (BioPharma Dive)
Mar-24-26 06:36AM	Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody (Pharmaceutical Business Review)
Mar-23-26 08:15AM	Earendil Labs lands $787m to fund biologics development push (Pharmaceutical Technology)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive)
Mar-20-26 09:13AM	Earendil Labs, an AI-powered drugmaker, hauls in $787M (BioPharma Dive)
Mar-17-26 02:32PM	Transient but transformative: Sanofis mRNA CAR-T enters in vivo race (Pharmaceutical Technology)
Mar-12-26 11:08PM	Vaxart Inc (VXRT) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-09-26 08:31PM	Analyst Report: Sanofi (Morningstar Research)
12:07PM	Dianthus Therapeutics Has Appreciated 13-Fold Over Two Years. What's Going On? (Investor's Business Daily)
09:35AM	Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026? (Zacks)
09:22AM	Dianthus Therapeutics Stock Rallies-Rare Disease Study Success Fuels Optimism (Benzinga)
Mar-06-26 02:33AM	Germanys Merck KGaA Expects Currency Headwinds to Weigh on Earnings (The Wall Street Journal)
Mar-05-26 08:02PM	Euroapi SA (EAPIF) Full Year 2025 Earnings Call Highlights: Strong EBITDA Growth Amid Sales ... (GuruFocus.com)
02:11PM	Podcast: Sanofis head of clinical supply chain operations on evolving the clinical trial supply model (Clinical Trials Arena)
Mar-04-26 02:02PM	Sanofi bets on Sino Biopharms transplant drug in $1.5bn licensing deal (Pharmaceutical Technology)
06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
Mar-03-26 10:50AM	Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU (Zacks)
10:00AM	Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan (Zacks)
04:46AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer (Zacks)
Mar-02-26 09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
08:39AM	4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam (Zacks)
08:16AM	Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial (The Wall Street Journal)
07:49AM	MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
05:59AM	Sanofi receives CHMP recommendation for Dupixent approval in Europe (Pharmaceutical Business Review)
Mar-01-26 04:26AM	Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval (Insider Monkey)
Feb-28-26 01:32PM	Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 (MarketBeat)
Feb-27-26 02:20PM	What's Going On With Novavax Stock On Friday? (Benzinga)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
08:26AM	Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates (Zacks)
01:54AM	Novavax Stock Hits Over 1-Year High: Is Sanofis Flu-COVID Shot The Post-Pandemic Growth Driver? (New feeds test provider finance)
12:07AM	Novavax Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 08:00PM	Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Call Highlights: Strategic Milestones and ... (GuruFocus.com)
05:03PM	Kymera Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:11PM	Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com)
04:08PM	Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
08:46AM	Novavax shares subdued despite earnings, revenue beat (Investing.com)
08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-25-26 05:25PM	Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk (MarketBeat)
05:25PM	Recursion Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
01:43PM	CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans (Zacks)
12:42AM	FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis (RTT News)
Feb-24-26 01:47PM	Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition (Benzinga)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:02AM	IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? (Zacks)
09:00AM	This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug (Barrons.com)
Feb-23-26 04:30PM	Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA (Insider Monkey)
07:38AM	Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff. (Barrons.com)
03:38AM	Merck to split cancer, specialty drug businesses in leadership shakeup (BioPharma Dive)
Feb-20-26 03:13PM	Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit (Insider Monkey)
01:36PM	Ex-Trump official-ran Altesa secures $75m in Series B funding round (Pharmaceutical Technology)
Feb-19-26 10:30AM	Moderna Stock Jumps After FDA Reverses Course on Flu Shot (Zacks)
Feb-18-26 10:10AM	FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer (Benzinga)
08:12AM	Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026? (Zacks)
Feb-17-26 09:15AM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga)
08:30AM	Sanofi announces leadership evolution in Specialty Care Business Unit (PR Newswire)
07:04AM	Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients (Benzinga)
Feb-16-26 08:59AM	RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? (Zacks)
04:40AM	Looking for Dividends? Consider Europe. (Barrons.com)
Feb-15-26 04:41AM	Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit (MarketBeat)
Feb-14-26 11:08AM	Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight (MarketBeat)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

CEO & DirectorMs. Belen Garijo Lopez M.D.

Executive VP & CFOMr. Francois-Xavier Roger

Executive VP & Head of Business OperationsMs. Madeleine Roach

Head of Investor Relations & General MedicinesMr. Thomas Kudsk Larsen

Executive VP & General CounselMr. Roy Papatheodorou

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Sanofi ADR

Upgrade your Finviz experience